Mercer Global Advisors Inc. ADV Increases Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Mercer Global Advisors Inc. ADV grew its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 86.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 17,412 shares of the medical equipment provider’s stock after purchasing an additional 8,083 shares during the quarter. Mercer Global Advisors Inc. ADV’s holdings in Zimmer Biomet were worth $1,839,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Stonebridge Financial Group LLC purchased a new position in Zimmer Biomet during the 4th quarter worth approximately $25,000. Kentucky Trust Co purchased a new position in shares of Zimmer Biomet during the fourth quarter worth approximately $39,000. OFI Invest Asset Management purchased a new stake in Zimmer Biomet in the 4th quarter valued at $40,000. SRS Capital Advisors Inc. boosted its stake in Zimmer Biomet by 146.9% during the 4th quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider’s stock worth $51,000 after purchasing an additional 285 shares during the period. Finally, Atala Financial Inc purchased a new position in Zimmer Biomet during the 4th quarter worth $51,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on ZBH shares. The Goldman Sachs Group lowered their price target on Zimmer Biomet from $120.00 to $104.00 and set a “neutral” rating on the stock in a report on Tuesday. JMP Securities dropped their target price on Zimmer Biomet from $140.00 to $125.00 and set a “market outperform” rating on the stock in a report on Wednesday. Robert W. Baird lowered their price objective on shares of Zimmer Biomet from $130.00 to $115.00 and set an “outperform” rating on the stock in a research report on Tuesday. Stifel Nicolaus set a $115.00 price objective on shares of Zimmer Biomet and gave the stock a “buy” rating in a research report on Tuesday. Finally, Truist Financial set a $101.00 target price on shares of Zimmer Biomet in a report on Tuesday. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $114.15.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $94.32 on Thursday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The stock has a market cap of $18.66 billion, a PE ratio of 21.20, a P/E/G ratio of 1.95 and a beta of 0.78. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.92 and a 1 year high of $122.25. The stock has a fifty day moving average price of $104.81 and a 200 day moving average price of $106.24.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The business had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. During the same period in the previous year, the firm earned $1.94 EPS. The business’s revenue for the quarter was up 1.1% compared to the same quarter last year. Sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 30th. Investors of record on Monday, March 31st were given a dividend of $0.24 per share. The ex-dividend date was Monday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 1.02%. Zimmer Biomet’s dividend payout ratio is currently 21.24%.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.39% of the stock is owned by insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.